Kaimen Rigor reviewed

Rigor-Reviewed Manuscript

Peri-operative atezolizumab in early-stage triple-negative breast cancer: final results and ctDNA analyses from the randomized phase 3 IMpassion031 trial.

Name: Kaimen Rigor review — Peri-operative atezolizumab in early-stage triple-negative breast cancer: final results and ctDNA analyses from the randomized phase 3 IMpassion031 trial.
Item: Peri-operative atezolizumab in early-stage triple-negative breast cancer: final results and ctDNA analyses from the randomized phase 3 IMpassion031 trial.
Rating: 59
Author: Alpha1

Mittendorf EA, Assaf ZJ, Harbeck N, Zhang H, Saji S, Jung KH, Hegg R, Koehler A, Sohn J, Iwata H, Telli ML, Ferrario C, Punie K, Qamra A, Dieterich M, Xu Y, Liste-Hermoso M, Shearer-Kang E, Molinero L, Chui SY, Barrios CH

Paper source

Read full text (PMC)

Embed this Rigor badge

Kaimen Rigor review — 1★ (Critical), 0 critical, 2 high issues for “Peri-operative atezolizumab in early-stage triple-negative breast cancer: final results and ctDNA analyses from the randomized phase 3 IMpassion031 trial.”

Links back to this Kaimen Rigor review.

Alpha1 Editorial

This rigor review was examined and confirmed by Alpha1 Editorial · August 15, 2026

Read alongside

Peri-operative atezolizumab in early-stage triple-negative breast cancer: final results and ctDNA analyses from the randomized phase 3 IMpassion031 trial.

Read full text (PMC)

DOI

10.1038/s41591-025-03725-4

Share this Kaimen Rigor review

Post on X Share on LinkedIn Share via Email

Embed this Rigor badge

<a href="https://alpha1science.com/verify/7bd9e270-1f19-44c5-ba10-9438bd023ff5" target="_blank" rel="noopener">
  <img src="https://alpha1science.com/verify/7bd9e270-1f19-44c5-ba10-9438bd023ff5/badge" alt="Kaimen Rigor review — 1★ (Critical), 0 critical, 2 high issues for “Peri-operative atezolizumab in early-stage triple-negative breast cancer: final results and ctDNA analyses from the randomized phase 3 IMpassion031 trial.”" width="440" height="104" style="max-width:100%;height:auto" />
</a>

Every embed links back to this Kaimen Rigor review.

Record fingerprint

a758d7b8eace73317ecf3cd7ccf6f274973e1ec4caa8cea1b0087314649a6167

Verify via API

Issued Aug 15, 2026Engine 7.39.0

Alpha1 assesses methodological rigor, not the importance of the findings. See how we calibrate →

Alpha¹ by Kaimen

Fetching the latest research

Kaimen Rigor reviewed

Rigor-Reviewed Manuscript

Peri-operative atezolizumab in early-stage triple-negative breast cancer: final results and ctDNA analyses from the randomized phase 3 IMpassion031 trial.

Paper source

Peri-operative atezolizumab in early-stage triple-negative breast cancer: final results and ctDNA analyses from the randomized phase 3 IMpassion031 trial.

Read full text (PMC)

Embed this Rigor badge

Links back to this Kaimen Rigor review.

Alpha1 Editorial

This rigor review was examined and confirmed by Alpha1 Editorial · August 15, 2026

Kaimen Rigor review

Kaimen Rigor reviewed

1 / 5

Critical — serious problems across many checks

Interventional Study

Critical

High-priority

How this rating was calculated▸

Started at 5★ — deductions

StatisticsStatistic did not reproduce ×2−1★
IntegrityIntegrity concern ×2−1★
CitationsCitations & links (capped) ×5−1★
ClaimsEfficacy rests on an unvalidated surrogate endpoint−0.5★
ClaimsTreatment effect not shown to be clinically meaningful−0.5★

Citations & links are capped at −1★ combined, however many are flagged.

Model-reported confidence: highReviewer agreement: highEngine: 7.39.0Source: full text

Biggest issues

01Printed percentage does not match its own count
highArithmeticrecomputedFull detail
56% does not match the reported count 43/67
“43 of 67 (56%)”
Find in source
02Printed percentage does not match its own count
highArithmeticrecomputedFull detail
56% does not match the reported count 43/67
“43 of 67 (56%)”
Placebo group, week 7 clearanceFind in source
03Efficacy rests on an unvalidated surrogate endpoint
highOverreachreviewer-assessedFull detail
The primary efficacy claim is based on pathologic complete response (pCR), a surrogate endpoint for long-term clinical outcomes. Although the trial also reports secondary endpoints like event-free survival (EFS), disease-free survival (DFS), and overall survival (OS), the primary endpoint and the main claim of improved outcomes are anchored on pCR. The paper does not provide evidence of target engagement at the tested dose (e.g., PK/PD data) nor does it cite validated evidence linking pCR to the clinical outcomes in this specific context. The discussion acknowledges that the trial was not powered for secondary endpoints and that pCR is a surrogate, but it does not establish the required link.
“At the primary analysis, the pathologic complete response (pCR) rate was improved significantly with the addition of atezolizumab to standard neoadjuvant chemotherapy. In the intention-to-treat (ITT) population, pCR rates were 58% with atezolizumab plus…”
Find in source
04Treatment effect not shown to be clinically meaningful
highOverreachreviewer-assessedFull detail
The primary reported effect is a 17% absolute improvement in pCR rate (from 41% to 58%). While statistically significant, the clinical meaningfulness of this surrogate endpoint is not anchored to a minimal clinically important difference or to long-term survival benefit. The secondary endpoints (EFS, DFS, OS) show hazard ratios below 1 but with confidence intervals crossing 1, and the trial was not powered for these. The effect size is presented without explicit anchoring to clinical meaningfulness beyond statistical significance.
“pCR rates were 58% with atezolizumab plus chemotherapy versus 41% with placebo plus chemotherapy, representing a 17% improvement (95% confidence interval (CI), 6–27%; 1-sided P = 0.0044, crossing the significance boundary).”
Find in source

Findings by category

201ArithmeticNumerical inconsistencies 202OverreachOverstated conclusions 103AuthenticityData authenticity concerns 04DisclosureNone found 105AvailabilityBroken references and links 06Copyedit5 minor suggestions

This Kaimen Rigor review uses Kaimen Rigor reviewers trained on a curated corpus of high-fidelity and retracted papers, with expert supervision and curation. It can still make mistakes; verify each finding against the source before relying on it.

This is a well-conducted randomized phase 3 trial with rigorous design, clear reporting of ethics, resources, and data availability. The main weaknesses are minor reporting gaps: the randomization method is not detailed in this paper, and the ctDNA-evaluable population is only 42% of ITT with reasons for non-evaluability not fully explained. The copyedit found only minor issues, and the citation check flagged 5 references not found in registries, which warrant verification.

Both reviewers classified the study as interventional; no divergence. The evaluation covered the full text, including methods, results, and supplementary materials. Non-applicable sub-criteria (e.g., animal housing, cell line authentication) were excluded. The statistics verification covered only a subset of tests (3 reported with test statistics/CIs), so the paper's statistics are not fully verified. The citation check flagged 5 references not found in registries, which are potential fabrication signals.

Numerical inconsistencies

2 findings · worst high

Values that contradict each other or are impossible for the stated sample: recomputed p-values and test statistics, GRIM/GRIMMER checks on summary numbers, percentages against their own counts, totals against their parts, and estimates against their own confidence intervals.

Summary statistic impossible for the stated N (GRIM/GRIMMER)Recomputed
Internal contradictions in the reported numbersAssessed

Recomputed 1 test: 1 consistent, 0 inconsistent; 1 via agent-written checks. 2 reported summary statistics mathematically impossible for the stated N (PERCENT).

Overstated conclusions

2 findings · worst high

Conclusions that reach past what the paper's own results support — including a significance claim that no longer holds when the statistic is recomputed, and efficacy resting on an unvalidated surrogate endpoint.

Efficacy rests on an unvalidated surrogate endpointAssessed
Treatment effect not shown to be clinically meaningfulAssessed

8 major claims checked against the paper's own evidence: all adequately supported.

Premise concern: surrogate not validated for clinical benefit; effect size not shown to be clinically meaningful.

Data authenticity concerns

1 finding · worst low

An adversarial read for patterns associated with data that may not be genuine: results that look too clean, implausibly large effects, duplicated data or images, and methods that do not match the results reported.

Other integrity concernAssessed

2 integrity concerns flagged (0 high).

Reporting gaps

None found

Required detail the manuscript never states — study design, biological variables, ethics approval and consent, key resources, statistical reporting, data and code availability, and overall transparency.

Checked — nothing surfaced.

Eight Dimensions8 pass

The introduction cites multiple randomized phase 3 trials (KEYNOTE-522, NeoTRIP, GeparNuevo) and prior ctDNA studies, acknowledging strengths and limitations. The rationale linking the premise to the study objectives is logical, and the paper explicitly addresses limitations of prior ctDNA research (e.g., few patients received immunotherapy).

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The paper establishes a clear scientific premise by citing prior trials of immune checkpoint inhibitors in TNBC and the rationale for ctDNA as a prognostic biomarker.

Evidence

“In patients on first-line treatment for advanced TNBC, benefit from immune checkpoint blockade is greatest in those with tumors expressing programmed death-ligand 1 (PD-L1) – . However, the benefit appears to be broader in randomized phase 3 trials of preoperative (neoadjuvant) therapy for early-stage TNBC, where the addition of immunotherapy improves the efficacy of chemotherapy regardless of PD-L1 status – .”

Introduction ¶1Find in source

“However, in both of these reports, very few patients received immunotherapy for TNBC, limiting their generalizability.”

Introduction ¶3Find in source

“The IMpassion031 dataset provided the opportunity to expand our understanding of ctDNA as a potential biomarker for individualizing immunotherapy-containing treatment for early-stage TNBC.”

Introduction ¶3Find in source

PASSReviewer 2· 90% conf

The paper establishes a clear scientific premise based on prior trials and identifies a gap in ctDNA data for immunotherapy-treated TNBC.

Evidence

paraphrase[Introduction, paragraphs 1-3]

“In a meta-analysis, the presence of ctDNA at baseline was associated with worse long-term outcomes, particularly if ctDNA persisted after therapy.”

“However, in both of these reports, very few patients received immunotherapy for TNBC, limiting their generalizability.”

Introduction ¶3Find in source

paraphrase[Introduction, paragraph 3]

“The IMpassion031 dataset provided the opportunity to expand understanding of ctDNA as a biomarker in immunotherapy-treated early-stage TNBC.”

Randomization method is stated (1:1 ratio, stratified by stage and PD-L1 status). Blinding is described (double-blind for neoadjuvant phase, open-label for adjuvant atezolizumab). Power analysis is referenced from the primary publication. Inclusion/exclusion criteria are detailed. Outlier handling is addressed via ITT and per-protocol analyses. Controls are the placebo group. Independent replication is not applicable for a single pivotal trial.

Sub-criteria

controlsADEQUATE

power analysisADEQUATE

blinding levelsADEQUATE

outlier handlingADEQUATE

randomization unitADEQUATE

inclusion exclusionADEQUATE

randomization methodADEQUATE

replicate distinctionN/A

independent replicationN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The trial design is rigorous: randomized, double-blind, with pre-specified endpoints and analysis populations; blinding and randomization are adequately described.

Evidence

“Eligible patients were randomized in a 1:1 ratio to receive either atezolizumab or placebo in combination with a neoadjuvant chemotherapy regimen comprising 12 weeks of nab-paclitaxel followed by 8 weeks of dose-dense doxorubicin plus cyclophosphamide, with filgrastim or pegfilgrastim support.”

Peri-operative atezolizumab in early-stage triple-negative breast cancer: final results and ctDNA analyses from the randomized phase 3 IMpassion031 trial.

Peri-operative atezolizumab in early-stage triple-negative breast cancer: final results and ctDNA analyses from the randomized phase 3 IMpassion031 trial.

Numerical inconsistencies

Overstated conclusions

Data authenticity concerns

Reporting gaps

Broken references and links

Copyediting

Numerical inconsistencies

Overstated conclusions

Data authenticity concerns

Reporting gaps

Broken references and links

Copyediting